首页 正文

Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum

{{output}}
The global incidence of steatotic liver disease (SLD), driven by metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the synergistic metabolic dysfunction and alcohol-associated liver disease (MetALD), ... ...